122 related articles for article (PubMed ID: 25254649)
1. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
2. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
[No Abstract] [Full Text] [Related]
5. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
7. EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate.
Matsumoto S; Saito K; Yasui H; Morris HD; Munasinghe JP; Lizak M; Merkle H; Ardenkjaer-Larsen JH; Choudhuri R; Devasahayam N; Subramanian S; Koretsky AP; Mitchell JB; Krishna MC
Magn Reson Med; 2013 May; 69(5):1443-50. PubMed ID: 22692861
[TBL] [Abstract][Full Text] [Related]
8. Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.
Ham SL; Joshi R; Luker GD; Tavana H
Adv Healthc Mater; 2016 Nov; 5(21):2788-2798. PubMed ID: 27603912
[TBL] [Abstract][Full Text] [Related]
9. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.
Cairns RA; Papandreou I; Sutphin PD; Denko NC
Proc Natl Acad Sci U S A; 2007 May; 104(22):9445-50. PubMed ID: 17517659
[TBL] [Abstract][Full Text] [Related]
10. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
[TBL] [Abstract][Full Text] [Related]
11.
Busk M; Eggertsen PP; Overgaard J; Horsman MR; Tørring T; Jacobsen KM; Poulsen TB
Anticancer Res; 2023 Dec; 43(12):5319-5329. PubMed ID: 38030202
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.
Stokes AM; Hart CP; Quarles CC
Tomography; 2016 Sep; 2(3):229-237. PubMed ID: 27752544
[TBL] [Abstract][Full Text] [Related]
13. Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs.
Mathur S; Chen S; Rejniak KA
NPJ Syst Biol Appl; 2024 Jan; 10(1):1. PubMed ID: 38182612
[TBL] [Abstract][Full Text] [Related]
14. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
[TBL] [Abstract][Full Text] [Related]
15. Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP).
Jagathesan K; Roy S
ChemMedChem; 2024 Apr; ():e202400127. PubMed ID: 38634306
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment.
Pan Y; Liu L; Mou X; Cai Y
ACS Nano; 2023 Nov; 17(21):20875-20924. PubMed ID: 37871328
[TBL] [Abstract][Full Text] [Related]
17. Deriving mechanisms responsible for the lack of correlation between hypoxia and acidity in solid tumors.
Molavian HR; Kohandel M; Milosevic M; Sivaloganathan S
PLoS One; 2011; 6(12):e28101. PubMed ID: 22174768
[TBL] [Abstract][Full Text] [Related]
18. Sensitive simultaneous measurements of oxygenation and extracellular pH by EPR using a stable monophosphonated trityl radical and lithium phthalocyanine.
Buyse C; Mignion L; Joudiou N; Melloul S; Driesschaert B; Gallez B
Free Radic Biol Med; 2024 Mar; 213():11-18. PubMed ID: 38218552
[TBL] [Abstract][Full Text] [Related]
19. Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2024 May; 30(10):2287. PubMed ID: 38745478
[No Abstract] [Full Text] [Related]
20. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.
Wojtkowiak JW; Cornnell HC; Matsumoto S; Saito K; Takakusagi Y; Dutta P; Kim M; Zhang X; Leos R; Bailey KM; Martinez G; Lloyd MC; Weber C; Mitchell JB; Lynch RM; Baker AF; Gatenby RA; Rejniak KA; Hart C; Krishna MC; Gillies RJ
Cancer Metab; 2015; 3(1):2. PubMed ID: 25635223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
